567 related articles for article (PubMed ID: 21294770)
1. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.
Hermanides J; Nørgaard K; Bruttomesso D; Mathieu C; Frid A; Dayan CM; Diem P; Fermon C; Wentholt IM; Hoekstra JB; DeVries JH
Diabet Med; 2011 Oct; 28(10):1158-67. PubMed ID: 21294770
[TBL] [Abstract][Full Text] [Related]
2. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
[TBL] [Abstract][Full Text] [Related]
3. The SWITCH study (sensing with insulin pump therapy to control HbA(1c)): design and methods of a randomized controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes suboptimally controlled with pump therapy.
Conget I; Battelino T; Giménez M; Gough H; Castañeda J; Bolinder J;
Diabetes Technol Ther; 2011 Jan; 13(1):49-54. PubMed ID: 21175271
[TBL] [Abstract][Full Text] [Related]
4. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.
Battelino T; Conget I; Olsen B; Schütz-Fuhrmann I; Hommel E; Hoogma R; Schierloh U; Sulli N; Bolinder J;
Diabetologia; 2012 Dec; 55(12):3155-62. PubMed ID: 22965294
[TBL] [Abstract][Full Text] [Related]
5. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
[TBL] [Abstract][Full Text] [Related]
6. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial.
O'Connell MA; Donath S; O'Neal DN; Colman PG; Ambler GR; Jones TW; Davis EA; Cameron FJ
Diabetologia; 2009 Jul; 52(7):1250-7. PubMed ID: 19396424
[TBL] [Abstract][Full Text] [Related]
7. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
[TBL] [Abstract][Full Text] [Related]
8. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.
Reznik Y; Cohen O; Aronson R; Conget I; Runzis S; Castaneda J; Lee SW;
Lancet; 2014 Oct; 384(9950):1265-72. PubMed ID: 24998009
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting improved glycaemic control in youth using insulin pumps.
Wilkinson J; McFann K; Chase HP
Diabet Med; 2010 Oct; 27(10):1174-7. PubMed ID: 20854386
[TBL] [Abstract][Full Text] [Related]
10. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
[TBL] [Abstract][Full Text] [Related]
11. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
[TBL] [Abstract][Full Text] [Related]
12. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data.
Pickup JC; Freeman SC; Sutton AJ
BMJ; 2011 Jul; 343():d3805. PubMed ID: 21737469
[TBL] [Abstract][Full Text] [Related]
13. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
Ly TT; Nicholas JA; Retterath A; Lim EM; Davis EA; Jones TW
JAMA; 2013 Sep; 310(12):1240-7. PubMed ID: 24065010
[TBL] [Abstract][Full Text] [Related]
14. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
[TBL] [Abstract][Full Text] [Related]
15. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
[TBL] [Abstract][Full Text] [Related]
16. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
[TBL] [Abstract][Full Text] [Related]
17. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.
Buse JB; Kudva YC; Battelino T; Davis SN; Shin J; Welsh JB
Diabetes Technol Ther; 2012 Jul; 14(7):644-7. PubMed ID: 22524549
[TBL] [Abstract][Full Text] [Related]
18. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability.
Pickup JC; Kidd J; Burmiston S; Yemane N
Diabetes Metab Res Rev; 2006; 22(3):232-7. PubMed ID: 16389648
[TBL] [Abstract][Full Text] [Related]
19. Sustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with Type 1 diabetes.
Beato-Víbora P; Yeoh E; Rogers H; Hopkins D; Amiel SA; Choudhary P
Diabet Med; 2015 Nov; 32(11):1453-9. PubMed ID: 26213236
[TBL] [Abstract][Full Text] [Related]
20. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
Blonde L; Merilainen M; Karwe V; Raskin P;
Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
